Pimecrolimus
- Generic Name
- Pimecrolimus
- Brand Names
- Elidel
- Drug Type
- Small Molecule
- Chemical Formula
- C43H68ClNO11
- CAS Number
- 137071-32-0
- Unique Ingredient Identifier
- 7KYV510875
- Background
Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
- Indication
For treatment of mild to moderate atopic dermatitis.
- Associated Conditions
- Vitiligo, Intertriginous psoriasis, Mild Atopic dermatitis, Moderate Atopic dermatitis
- Associated Therapies
- -
5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2005-07-18
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 2418
- Registration Number
- NCT00120523
- Locations
- 🇺🇸
Children's Skin Center, Miami, Florida, United States
🇺🇸Dermatology Research Associates, Cincinnati, Ohio, United States
🇩🇪Novartis, Investigative Site, Germany
Quality of Life Study in Adults With Facial Eczema
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 76
- Registration Number
- NCT00120302
- Locations
- 🇬🇧
This study is not being conducted in the United States, Novartis Pharmaceuticals UK, Frimley, United Kingdom
Combination Therapy for Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2005-07-13
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 90
- Registration Number
- NCT00119158
- Locations
- 🇺🇸
Northwestern University School of Medicine, Chicago, Illinois, United States
🇺🇸National Jewish Research Medical Center, Denver, Colorado, United States
🇺🇸University of Texas at Houston Medical School, Houston, Texas, United States
Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 70
- Registration Number
- NCT00117377
- Locations
- 🇺🇸
Virginia Clinical Research, Inc, Norfolk, Virginia, United States
🇺🇸New York University Hospital, New York, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.